LQDA Downgraded as Stock Collapses 57% in a Day

Liquidia Corporation shed 57% on 1 October. BTIG's Julian Harrison, who had a Buy rating and a $111 price target as recently as August, cut to Neutral the same morning.

The Analyst Reversal

Harrison's downgrade arrived without a new price target, a signal of deep uncertainty rather than a measured reset. Needham's Serge Belanger held his Buy but slashed his target from $110 to $72, a 35% cut. The consensus mean target still sits at $81.86, but that figure will lag the move; targets set before a one-day collapse of this magnitude are stale by definition.

The bear case had been building for months. YUTREPIA posted an 11% sequential sales decline despite management expanding the sales force by a third. Analysts had cited limited differentiation versus competitor products, cash pressure, and ongoing patent litigation risk. The August earnings print sent the stock down 18% in a single day. Tuesday's move dwarfs that.

What Shorts and Options Were Saying

The previous two ORTEX articles on this stock noted a tension: short sellers were building aggressively while options traders refused to hedge. That tension has now resolved, painfully, in the bears' favour.

Short interest climbed to 15.6% of free float by 29 September, up 20% over the month. The ORTEX short score was 71, placing LQDA in the bottom 11th percentile for short score rank. Director Raman Singh sold roughly $1.2M in open-market shares across 11 and 14 September, without a pre-arranged 10b5-1 plan. The net insider position over 90 days stood at minus $48.8M in value.

The options market had been running a put/call ratio of 0.32 against a 20-day mean of 0.38, a full standard deviation more bullish than average. Those calls are now deeply out of the money.

Borrow Market After the Fall

Availability in the lending market stood at 325% as of 29 September, meaning roughly three shares remained available to borrow for every one already lent out. Cost to borrow was 0.29%, down 48% on the week. Those readings will almost certainly shift materially when settlement catches up with the 1 October move. Shorts who were right face a very different borrow market going forward.

Retail attention had spiked 4.5 standard deviations above its own 90-day history as of 27 September, per Wikipedia views and ORTEX stock page traffic. That surge in engagement preceded the collapse by four days.

Data Summary

• Price close 30 September: $30.26, down 57.2% on the day
• SI % of free float (29 Sep): 15.6%, up 20% over one month
• ORTEX short score: 71 (11th percentile for short score rank)
• Borrow availability (29 Sep): 325%; cost to borrow 0.29%
• BTIG: downgraded to Neutral from Buy, 1 October
• Needham: Buy maintained, target cut from $110 to $72
• Net insider selling (90 days to 14 Sep): minus $48.8M
• Director Singh: sold $1.2M in open-market shares, no 10b5-1 plan
• Next earnings: 5 November 2026